Dostarlimab

Generic Name
Dostarlimab
Brand Names
Jemperli
Drug Type
Biotech
Chemical Formula
-
CAS Number
2022215-59-2
Unique Ingredient Identifier
P0GVQ9A4S5
Background

Dostarlimab is an IgG humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically att...

Indication

Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.
...

Associated Conditions
Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer, Advanced Mismatch repair deficient (dMMR) solid tumors, Recurrent Microsatellite Instability (MSI)-High Endometrial Cancer, Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer, Recurrent Mismatch repair deficient (dMMR) solid tumors
Associated Therapies
-
onclive.com
·

MI Cancer Seek Receives FDA Approval as Companion Diagnostic for Targeted Therapy

FDA approves MI Cancer Seek as companion diagnostic for cancer patients aged 1-22, offering comprehensive molecular profiling via whole-exome and whole-transcriptome sequencing. The diagnostic includes indications for breast, colorectal, melanoma, non-small cell lung, endometrial, and solid tumors, aiding in targeted therapy decisions.
onclive.com
·

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens

ESMO 2024 Congress featured updates on ovarian, cervical, and endometrial cancers, including niraparib's long-term PFS benefit, gotistobart's potential in platinum-resistant disease, and T-DXd's tumor-agnostic approval. Checkpoint inhibitors are integrating into cervical and endometrial cancer treatments, with clinical trials showing benefits in PFS and OS. ADCs like tisotumab vedotin and TROP2-directed ADCs are emerging as therapeutic options, particularly in endometrial cancer.
quantisnow.com
·

Amendment: SEC Form S-1/A filed by Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings, Inc. filed an Amendment No. 1 to Form S-1 Registration Statement with the SEC on November 1, 2024, for the offering of up to 1,895,734 Units, each consisting of one share of common stock or one pre-funded warrant to purchase one share of common stock and 1.25 common warrants to purchase one share of common stock, aiming to raise up to approximately $4,000,000. The offering is conducted on a reasonable best efforts basis, with WallachBeth Capital LLC as the exclusive placement agent. The company intends to use the net proceeds for working capital and general corporate purposes. The securities are offered at a fixed price, expected to be issued in a single closing, and the offering will end no later than November 30, 2024. The company faces risks related to development and regulatory approval of its product candidates, including potential clinical trial holds due to serious adverse events, and compliance with Nasdaq listing requirements.
aacr.org
·

FDA Approvals in Oncology: July-September 2024

The FDA approved 16 oncology therapies in Q3 2024, including first-in-class TCR T-cell therapy afami-cel for synovial cell sarcoma, denileukin diftitox for cutaneous T-cell lymphoma, and axatilimab-csfr for chronic graft-versus-host disease. Vorasidenib was approved for grade 2 astrocytoma or oligodendroglioma, and three EGFR-targeting therapies for non-small cell lung cancer. New formulations of atezolizumab and daratumumab with hyaluronidase were approved, along with expanded indications for durvalumab, isatuximab, and ribociclib. Selpercatinib was approved for pediatric medullary thyroid cancer, and pembrolizumab and dostarlimab-gxly received biomarker-agnostic approvals for malignant pleural mesothelioma and endometrial cancer, respectively.
onclive.com
·

FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer

The FDA granted fast track designation to EO-3021 (SYSA1801) for advanced or metastatic CLDN18.2-expressing gastric or gastroesophageal junction cancer. Initial phase 1 study data showed EO-3021 was well-tolerated with a 42.8% objective response rate in CLDN18.2-enriched gastric and gastroesophageal junction cancer patients. The study will expand to explore EO-3021 in combination with other treatments.
© Copyright 2024. All Rights Reserved by MedPath